Search research articles
Contact Us
Filters
Showing results (1-10 of 50) with videos related to
Page
of 5
Sort By:
Blood Reviews
|
July 23, 2008
Protease-activated receptors as targets for antiplatelet therapy
Justin R Hamilton
Annual Review of Pharmacology and Toxicology
|
September 14, 2016
Challenges and Opportunities in Protease-Activated Receptor Drug Development
Justin R Hamilton, JoAnn Trejo
Pharmacology & Therapeutics
|
February 14, 2012
Physiology, pharmacology, and therapeutic potential of protease-activated receptors in vascular disease
Hannah Lee, Justin R Hamilton
Thrombosis and Haemostasis
|
October 25, 2012
The PAR1 antagonist, SCH79797, alters platelet morphology and function independently of PARs
Hannah Lee, Justin R Hamilton
Platelets
|
September 30, 2017
Perinatal lethality of Par4<sup>-/-</sup> mice delivered by primiparous dams reveals spontaneous bleeding in mice without platelet thrombin receptor function
Shauna L French, Justin R Hamilton
Annals of Translational Medicine
|
December 30, 2017
Drugs targeting protease-activated receptor-4 improve the anti-thrombotic therapeutic window
Shauna L French, Justin R Hamilton
British Journal of Pharmacology
|
February 5, 2016
Protease-activated receptor 4: from structure to function and back again
Shauna L French, Justin R Hamilton
Platelets
|
February 15, 2018
Structure and function of the open canalicular system - the platelet's specialized internal membrane network
Maria V Selvadurai, Justin R Hamilton
International Journal of Molecular Sciences
|
November 14, 2019
Using PAR4 Inhibition as an Anti-Thrombotic Approach: Why, How, and When?
Simeng Li, Volga Tarlac, Justin R Hamilton
International Journal of Molecular Sciences
|
May 14, 2022
Phosphoinositide 3-Kinases as Potential Targets for Thrombosis Prevention
Natasha M Setiabakti, Pia Larsson, Justin R Hamilton
Page
of 5
Search research articles
Search
Showing results (1-10 of 50) with videos related to
Sort By:
Page
of 5
Blood Reviews
|
July 23, 2008
Protease-activated receptors as targets for antiplatelet therapy
Justin R Hamilton
Annual Review of Pharmacology and Toxicology
|
September 14, 2016
Challenges and Opportunities in Protease-Activated Receptor Drug Development
Justin R Hamilton, JoAnn Trejo
Pharmacology & Therapeutics
|
February 14, 2012
Physiology, pharmacology, and therapeutic potential of protease-activated receptors in vascular disease
Hannah Lee, Justin R Hamilton
Thrombosis and Haemostasis
|
October 25, 2012
The PAR1 antagonist, SCH79797, alters platelet morphology and function independently of PARs
Hannah Lee, Justin R Hamilton
Platelets
|
September 30, 2017
Perinatal lethality of Par4<sup>-/-</sup> mice delivered by primiparous dams reveals spontaneous bleeding in mice without platelet thrombin receptor function
Shauna L French, Justin R Hamilton
Annals of Translational Medicine
|
December 30, 2017
Drugs targeting protease-activated receptor-4 improve the anti-thrombotic therapeutic window
Shauna L French, Justin R Hamilton
British Journal of Pharmacology
|
February 5, 2016
Protease-activated receptor 4: from structure to function and back again
Shauna L French, Justin R Hamilton
Platelets
|
February 15, 2018
Structure and function of the open canalicular system - the platelet's specialized internal membrane network
Maria V Selvadurai, Justin R Hamilton
International Journal of Molecular Sciences
|
November 14, 2019
Using PAR4 Inhibition as an Anti-Thrombotic Approach: Why, How, and When?
Simeng Li, Volga Tarlac, Justin R Hamilton
International Journal of Molecular Sciences
|
May 14, 2022
Phosphoinositide 3-Kinases as Potential Targets for Thrombosis Prevention
Natasha M Setiabakti, Pia Larsson, Justin R Hamilton
Page
of 5